- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-3138
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? ; volume:19 ; number:8 ; day:27 ; month:6 ; year:2017 ; pages:1-11 ; date:8.2017
Current treatment options in neurology ; 19, Heft 8 (27.6.2017), 1-11, 8.2017
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Tso, Amy R.
- Beteiligte Personen und Organisationen
-
Goadsby, Peter J.
SpringerLink (Online service)
- DOI
-
10.1007/s11940-017-0463-4
- URN
-
urn:nbn:de:1111-201708049877
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:40 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tso, Amy R.
- Goadsby, Peter J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Monoclonal antibodies for migraine: an update
Inflammatory complications of CGRP monoclonal antibodies: a case series
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study